1. In Vivo

Ups And Downs Of Anti-TIGIT Development

A Look Back At 2023 And What's To Come In 2024

 
• By David Wild

Once heralded with optimism, the class of anti-TIGIT molecules has since fallen out of favor, plagued by a succession of disappointing findings.

The Potential Of Anti-TIGITs May Become Clearer In 2024 • Source: Shutterstock

Looking back on 2023, Merck & Co., Inc. and Roche Holding AG released less-than-impressive findings on their anti-TIGIT combinations in non-small cell lung cancer (NSCLC). The bright spot last year was Arcus Biosciences, Inc. and Gilead Sciences, Inc.’s anti-TIGIT/anti-programmed cell death ligand 1 (PD-L1) coformulation in gastric cancer, which showed greater efficacy than the standard of care for gastric cancers, particularly in high-PD-L1 expressers. 

“Whilst it seems hope is not lost for the TIGIT drug class, Phase II data will not be sufficient to...

More from Market Intelligence

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.